<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05011500</url>
  </required_header>
  <id_info>
    <org_study_id>CTOR20051GZA</org_study_id>
    <nct_id>NCT05011500</nct_id>
  </id_info>
  <brief_title>Masks Against Surface-Scanning for Radiation Therapy Immobilisation in Head and Neck Cancer (MASSC)</brief_title>
  <acronym>MASSC</acronym>
  <official_title>Masks Against Surface-Scanning for Radiation Therapy Immobilisation in Head and Neck Cancer (MASSC Study)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cancer Research Antwerp</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cancer Research Antwerp</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate the feasibility of using open masks or no masks&#xD;
      in combination with optical surface scanning for radiotherapy in patients with head and neck&#xD;
      cancer.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">June 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Positional Deviation</measure>
    <time_frame>Positional Deviation will be assessed from start of treatment period to end of treatment period (up to 7 weeks).</time_frame>
    <description>Patient positioning and movement during treatment will be assessed using cone-beam computed tomopgraphy (CBCT). The position of the patient and target volumes measured by CBCT will be compared to computed tomography (CT) scans made during the initial simulation of treatment. CBCT-scans are made right before administering radiation and after radiation has been administered. Translational and rotational deviations will be measured and expressed in millimeters (for translational deviation) and degrees (for rotational deviation).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patient Distress</measure>
    <time_frame>Patient distress will be assessed from start of treatment period to end of treatment period (up to 7 weeks).</time_frame>
    <description>Patient Distress, measured every week using the Subjective Units of Distress Scale (SUDs), a scale of 0-10 where a higher number indicates a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Treatment</measure>
    <time_frame>Duration of treatment will be assessed from start of treatment period to end of treatment period (up to 7 weeks).</time_frame>
    <description>Duration of treatment (in minutes), registered in radiotherapy software.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiotherapy Technician Satisfaction</measure>
    <time_frame>Radiotherapy technician satisfaction will be assessed from start of treatment period to end of treatment period (up to 7 weeks).</time_frame>
    <description>Personnel satisfaction, questioned weekly using a personnel satisfaction scale from 0 to 10, where a higher number indicates a better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Radiation Dose</measure>
    <time_frame>Radiation dose will be assessed from start of treatment period to end of treatment period (up to 7 weeks).</time_frame>
    <description>In vivo dosimetry will be used to asses the accuracy of treatment. Using PerFRACTION™ in vivo dosimetry. Administered radiation doses will be measured for the target volume and expressed in Gray (Gy).</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Head and Neck Neoplasm</condition>
  <arm_group>
    <arm_group_label>Starting with closed mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient 1-8, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using a closed mask. For the next 5 fractions these patients will receive radiotherapy using an open mask. For the 5 fractions after that these patients will receive radiotherapy using no mask. This schedule repeats for the rest of their treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starting with open mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient 9-16, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using an open mask. For the next 5 fractions these patients will receive radiotherapy using no mask. For the 5 fractions after that these patients will receive radiotherapy using a closed mask. This schedule repeats for the rest of their treatment.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Starting with no mask</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient 17-24, receiving radiotherapy for head and neck cancer in this study. Patients will receive 35 fractions of radiotherapy in total. For the first 5 fractions these patients will receive radiotherapy using no mask. For the next 5 fractions these patients will receive radiotherapy using a closed mask. For the 5 fractions after that these patients will receive radiotherapy using an open mask. This schedule repeats for the rest of their treatment.</description>
  </arm_group>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with Closed Mask</intervention_name>
    <description>Radiotherapy for head and neck cancer, using a closed mask (full thermoplastic mask) to restrict patient movement.</description>
    <arm_group_label>Starting with closed mask</arm_group_label>
    <arm_group_label>Starting with no mask</arm_group_label>
    <arm_group_label>Starting with open mask</arm_group_label>
    <other_name>Full thermoplastic mask</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with Open Mask and Surface Scanning</intervention_name>
    <description>Radiotherapy for head and neck cancer, using an open mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.</description>
    <arm_group_label>Starting with closed mask</arm_group_label>
    <arm_group_label>Starting with no mask</arm_group_label>
    <arm_group_label>Starting with open mask</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiotherapy with No Mask</intervention_name>
    <description>Radiotherapy for head and neck cancer, without using a mask to restrict patient movement. Surface Scanning is used to monitor patient movement/positioning.</description>
    <arm_group_label>Starting with closed mask</arm_group_label>
    <arm_group_label>Starting with no mask</arm_group_label>
    <arm_group_label>Starting with open mask</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients ≥ 18 years old&#xD;
&#xD;
          -  Histologically confirmed head and neck cancer.&#xD;
&#xD;
          -  Patients treated with radiotherapy (RT) as primary treatment.&#xD;
&#xD;
          -  An Eastern Cooperative Oncology Group (ECOG) Performance Status grade of 0-1 as&#xD;
             defined in Appendix 3.&#xD;
&#xD;
          -  Each subject must sign an informed consent form (ICF) indicating that he understands&#xD;
             the purpose of and procedures required for the study and is willing to participate in&#xD;
             the study.&#xD;
&#xD;
          -  Patients must be willing to comply with treatment plan and other study procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with significantly altered mental status or with psychological, familial,&#xD;
             sociological or geographical condition potentially hampering compliance with the&#xD;
             study.&#xD;
&#xD;
          -  Patients who cannot stay still during fraction because of a disorder (e.g. Parkinson's&#xD;
             disease)&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daan Nevens, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Research Antwerp</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Daan Nevens, PhD</last_name>
    <phone>0032034433737</phone>
    <phone_ext>+32</phone_ext>
    <email>Daan.Nevens@gza.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>GZA Ziekenhuizen campus Sint-Augustinus</name>
      <address>
        <city>Antwerp</city>
        <zip>2610</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daan Nevens, PhD</last_name>
      <phone>0032034433737</phone>
      <phone_ext>+32</phone_ext>
      <email>Daan.Nevens@gza.be</email>
    </contact>
    <investigator>
      <last_name>Daan Nevens, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <reference>
    <citation>Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7. Erratum in: CA Cancer J Clin. 2014 Sep-Oct;64(5):364.</citation>
    <PMID>24399786</PMID>
  </reference>
  <reference>
    <citation>Wiant D, Squire S, Liu H, Maurer J, Lane Hayes T, Sintay B. A prospective evaluation of open face masks for head and neck radiation therapy. Pract Radiat Oncol. 2016 Nov - Dec;6(6):e259-e267. doi: 10.1016/j.prro.2016.02.003. Epub 2016 Feb 13.</citation>
    <PMID>27025164</PMID>
  </reference>
  <reference>
    <citation>Li G, Lovelock DM, Mechalakos J, Rao S, Della-Biancia C, Amols H, Lee N. Migration from full-head mask to &quot;open-face&quot; mask for immobilization of patients with head and neck cancer. J Appl Clin Med Phys. 2013 Sep 6;14(5):243-54. doi: 10.1120/jacmp.v14i5.4400.</citation>
    <PMID>24036878</PMID>
  </reference>
  <reference>
    <citation>Zhao B, Maquilan G, Jiang S, Schwartz DL. Minimal mask immobilization with optical surface guidance for head and neck radiotherapy. J Appl Clin Med Phys. 2018 Jan;19(1):17-24. doi: 10.1002/acm2.12211. Epub 2017 Nov 9.</citation>
    <PMID>29119677</PMID>
  </reference>
  <reference>
    <citation>Dekker J, Rozema T, Böing-Messing F, Garcia M, Washington D, de Kruijf W. Whole-brain radiation therapy without a thermoplastic mask. Phys Imaging Radiat Oncol. 2019 Jul 25;11:27-29. doi: 10.1016/j.phro.2019.07.004. eCollection 2019 Jul.</citation>
    <PMID>33458273</PMID>
  </reference>
  <reference>
    <citation>Ali I, Matthiesen C, Algan O, Thompson S, Bogardus C, Herman T, Ahmad S. Quantitative evaluation of increase in surface dose by immobilization thermoplastic masks and superficial dosimetry using Gafchromic EBT film and Monte Carlo calculations. J Xray Sci Technol. 2010;18(3):319-26. doi: 10.3233/XST-2010-0263.</citation>
    <PMID>20714089</PMID>
  </reference>
  <reference>
    <citation>Stieler F, Wenz F, Shi M, Lohr F. A novel surface imaging system for patient positioning and surveillance during radiotherapy. A phantom study and clinical evaluation. Strahlenther Onkol. 2013 Nov;189(11):938-44. doi: 10.1007/s00066-013-0441-z. Epub 2013 Sep 27.</citation>
    <PMID>24068172</PMID>
  </reference>
  <reference>
    <citation>Cerviño LI, Pawlicki T, Lawson JD, Jiang SB. Frame-less and mask-less cranial stereotactic radiosurgery: a feasibility study. Phys Med Biol. 2010 Apr 7;55(7):1863-73. doi: 10.1088/0031-9155/55/7/005. Epub 2010 Mar 12.</citation>
    <PMID>20224158</PMID>
  </reference>
  <reference>
    <citation>Bartlett FR, Donovan EM, McNair HA, Corsini LA, Colgan RM, Evans PM, Maynard L, Griffin C, Haviland JS, Yarnold JR, Kirby AM. The UK HeartSpare Study (Stage II): Multicentre Evaluation of a Voluntary Breath-hold Technique in Patients Receiving Breast Radiotherapy. Clin Oncol (R Coll Radiol). 2017 Mar;29(3):e51-e56. doi: 10.1016/j.clon.2016.11.005. Epub 2016 Nov 24.</citation>
    <PMID>27890346</PMID>
  </reference>
  <reference>
    <citation>van Herk M. Errors and margins in radiotherapy. Semin Radiat Oncol. 2004 Jan;14(1):52-64. Review.</citation>
    <PMID>14752733</PMID>
  </reference>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>April 29, 2021</study_first_submitted>
  <study_first_submitted_qc>August 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 18, 2021</study_first_posted>
  <last_update_submitted>August 17, 2021</last_update_submitted>
  <last_update_submitted_qc>August 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Radiotherapy</keyword>
  <keyword>Radiotherapy, Image-Guided</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 12, 2021</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/00/NCT05011500/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

